Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 328

1.

Establishing a cryopreservation protocol for patient-derived xenografts of prostate cancer.

Porter LH, Lawrence MG, Wang H, Clark AK, Bakshi A, Obinata D, Goode D, Papargiris M, Mural, Clouston D, Ryan A, Norden S, Corey E, Nelson PS, Isaacs JT, Grummet J, Kourambas J, Sandhu S, Murphy DG, Pook D, Frydenberg M, Taylor RA, Risbridger GP.

Prostate. 2019 Aug;79(11):1326-1337. doi: 10.1002/pros.23839. Epub 2019 Jun 18.

PMID:
31212368
2.

Asporin Restricts Mesenchymal Stromal Cell Differentiation, Alters the Tumor Microenvironment, and Drives Metastatic Progression.

Hughes RM, Simons BW, Khan H, Miller R, Kugler V, Torquato S, Theodros D, Haffner MC, Lotan T, Huang J, Davicioni E, An SS, Riddle RC, Thorek DLJ, Garraway IP, Fertig EJ, Isaacs JT, Brennen WN, Park BH, Hurley PJ.

Cancer Res. 2019 Jul 15;79(14):3636-3650. doi: 10.1158/0008-5472.CAN-18-2931. Epub 2019 May 23.

PMID:
31123087
3.

In Reply.

Brennen WN, Schweizer MT, Wang H, Bivalacqua TJ, Partin AW, Lim SJ, Chapman C, Abdallah R, Levy O, Bhowmick NA, Karp JM, De Marzo A, Isaacs JT, Denmeade SR.

Stem Cells Transl Med. 2019 Jul;8(7):739-740. doi: 10.1002/sctm.19-0068. Epub 2019 Mar 29. No abstract available.

4.

Albumin-linked prostate-specific antigen-activated thapsigargin- and niclosamide-based molecular grenades targeting the microenvironment in metastatic castration-resistant prostate cancer.

Akinboye ES, Brennen WN, Denmeade SR, Isaacs JT.

Asian J Urol. 2019 Jan;6(1):99-108. doi: 10.1016/j.ajur.2018.11.004. Epub 2018 Nov 28. Review.

5.

A Phase I Study to Assess the Safety and Cancer-Homing Ability of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Men with Localized Prostate Cancer.

Schweizer MT, Wang H, Bivalacqua TJ, Partin AW, Lim SJ, Chapman C, Abdallah R, Levy O, Bhowmick NA, Karp JM, De Marzo A, Isaacs JT, Brennen WN, Denmeade SR.

Stem Cells Transl Med. 2019 May;8(5):441-449. doi: 10.1002/sctm.18-0230. Epub 2019 Feb 8.

6.

Tumor-infiltrating mesenchymal stem cells: Drivers of the immunosuppressive tumor microenvironment in prostate cancer?

Krueger TE, Thorek DLJ, Meeker AK, Isaacs JT, Brennen WN.

Prostate. 2019 Feb;79(3):320-330. doi: 10.1002/pros.23738. Epub 2018 Nov 28.

7.

Pharmacologic Exhaustion of Suppressor Cells with Tasquinimod Enhances Bacterial Clearance during Tuberculosis.

Gupta S, Krug S, Pokkali S, Leanderson T, Isaacs JT, Srikrishna G, Bishai WR.

Am J Respir Crit Care Med. 2019 Feb 1;199(3):386-389. doi: 10.1164/rccm.201805-0820LE. No abstract available.

PMID:
30395729
8.

Checks and balances occur not only in government, but also in biology.

Isaacs JT.

Oncotarget. 2018 Sep 4;9(69):33054-33055. doi: 10.18632/oncotarget.25876. eCollection 2018 Sep 4. No abstract available.

9.

Mesenchymal stem cells and the embryonic reawakening theory of BPH.

Brennen WN, Isaacs JT.

Nat Rev Urol. 2018 Nov;15(11):703-715. doi: 10.1038/s41585-018-0087-9. Review.

PMID:
30214054
10.

Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.

Navone NM, van Weerden WM, Vessella RL, Williams ED, Wang Y, Isaacs JT, Nguyen HM, Culig Z, van der Pluijm G, Rentsch CA, Marques RB, de Ridder CMA, Bubendorf L, Thalmann GN, Brennen WN, Santer FR, Moser PL, Shepherd P, Efstathiou E, Xue H, Lin D, Buijs J, Bosse T, Collins A, Maitland N, Buzza M, Kouspou M, Achtman A, Taylor RA, Risbridger G, Corey E.

Prostate. 2018 Dec;78(16):1262-1282. doi: 10.1002/pros.23701. Epub 2018 Aug 2.

PMID:
30073676
11.

Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise.

Krueger TEG, Thorek DLJ, Denmeade SR, Isaacs JT, Brennen WN.

Stem Cells Transl Med. 2018 Sep;7(9):651-663. doi: 10.1002/sctm.18-0024. Epub 2018 Aug 1. Review.

12.
13.

The what, when, and why of human prostate cancer xenografts.

Brennen WN, Isaacs JT.

Prostate. 2018 Jun;78(9):646-654. doi: 10.1002/pros.23510. Epub 2018 Mar 24. Review.

PMID:
29575112
14.

2-fluoro-5-maleimidobenzoic acid-linked albumin drug (MAD) delivery for selective systemic targeting of metastatic prostate cancer.

Akinboye ES, Rogers OC, Isaacs JT.

Prostate. 2018 Jun;78(9):655-663. doi: 10.1002/pros.23494. Epub 2018 Mar 24.

15.

Cellular Origin of Androgen Receptor Pathway-Independent Prostate Cancer and Implications for Therapy.

Brennen WN, Isaacs JT.

Cancer Cell. 2017 Oct 9;32(4):399-401. doi: 10.1016/j.ccell.2017.09.011.

16.

Rationale for bipolar androgen therapy (BAT) for metastatic prostate cancer.

Isaacs JT, Brennen WN, Denmeade SR.

Cell Cycle. 2017 Sep 17;16(18):1639-1640. doi: 10.1080/15384101.2017.1360645. Epub 2017 Aug 18. No abstract available.

17.

Mesenchymal stem cell infiltration during neoplastic transformation of the human prostate.

Brennen WN, Zhang B, Kulac I, Kisteman LN, Antony L, Wang H, Meeker AK, De Marzo AM, Garraway IP, Denmeade SR, Isaacs JT.

Oncotarget. 2017 Jul 18;8(29):46710-46727. doi: 10.18632/oncotarget.17362.

18.

Low p16INK4a Expression in Early Passage Human Prostate Basal Epithelial Cells Enables Immortalization by Telomerase Expression Alone.

Graham MK, Principessa L, Antony L, Meeker AK, Isaacs JT.

Prostate. 2017 Mar;77(4):374-384. doi: 10.1002/pros.23276. Epub 2016 Nov 8.

19.

Assessing angiogenic responses induced by primary human prostate stromal cells in a three-dimensional fibrin matrix assay.

Brennen WN, Nguyen H, Dalrymple SL, Reppert-Gerber S, Kim J, Isaacs JT, Hammers H.

Oncotarget. 2016 Nov 1;7(44):71298-71308. doi: 10.18632/oncotarget.11347.

20.

Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer.

Guedes LB, Morais CL, Almutairi F, Haffner MC, Zheng Q, Isaacs JT, Antonarakis ES, Lu C, Tsai H, Luo J, De Marzo AM, Lotan TL.

Clin Cancer Res. 2016 Sep 15;22(18):4651-63. doi: 10.1158/1078-0432.CCR-16-0205. Epub 2016 May 10.

21.

A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer.

Levy O, Brennen WN, Han E, Rosen DM, Musabeyezu J, Safaee H, Ranganath S, Ngai J, Heinelt M, Milton Y, Wang H, Bhagchandani SH, Joshi N, Bhowmick N, Denmeade SR, Isaacs JT, Karp JM.

Biomaterials. 2016 Jun;91:140-150. doi: 10.1016/j.biomaterials.2016.03.023. Epub 2016 Mar 17.

22.

Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation.

Hedayati M, Haffner MC, Coulter JB, Raval RR, Zhang Y, Zhou H, Mian O, Knight EJ, Razavi N, Dalrymple S, Isaacs JT, Santos A, Hales R, Nelson WG, Yegnasubramanian S, DeWeese TL.

Clin Cancer Res. 2016 Jul 1;22(13):3310-3319. doi: 10.1158/1078-0432.CCR-15-1147. Epub 2016 Feb 1.

23.

Rapid selection of mesenchymal stem and progenitor cells in primary prostate stromal cultures.

Brennen WN, Kisteman LN, Isaacs JT.

Prostate. 2016 May;76(6):552-64. doi: 10.1002/pros.23145. Epub 2016 Jan 6.

24.

Lessons learned about prostatic transformation from the age-related methylation of 5α-reductase type 2 gene.

Isaacs JT.

Am J Pathol. 2015 Mar;185(3):614-6. doi: 10.1016/j.ajpath.2015.01.001. Epub 2015 Feb 17.

25.

Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study.

Schweizer MT, Antonarakis ES, Wang H, Ajiboye AS, Spitz A, Cao H, Luo J, Haffner MC, Yegnasubramanian S, Carducci MA, Eisenberger MA, Isaacs JT, Denmeade SR.

Sci Transl Med. 2015 Jan 7;7(269):269ra2. doi: 10.1126/scitranslmed.3010563.

26.

Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment.

Isaacs JT, Dalrymple SL, Rosen DM, Hammers H, Olsson A, Leanderson T.

Oncotarget. 2014 Sep 30;5(18):8093-106.

27.

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J.

N Engl J Med. 2014 Sep 11;371(11):1028-38. doi: 10.1056/NEJMoa1315815. Epub 2014 Sep 3.

28.

Targeting thapsigargin towards tumors.

Doan NT, Paulsen ES, Sehgal P, Møller JV, Nissen P, Denmeade SR, Isaacs JT, Dionne CA, Christensen SB.

Steroids. 2015 May;97:2-7. doi: 10.1016/j.steroids.2014.07.009. Epub 2014 Jul 24. Review.

29.

Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)-activated prodrug in murine xenograft models of human cancer.

Brennen WN, Rosen DM, Chaux A, Netto GJ, Isaacs JT, Denmeade SR.

Prostate. 2014 Sep;74(13):1308-19. doi: 10.1002/pros.22847. Epub 2014 Jul 22.

30.
31.

Androgen receptor (AR) suppresses normal human prostate epithelial cell proliferation via AR/β-catenin/TCF-4 complex inhibition of c-MYC transcription.

Antony L, van der Schoor F, Dalrymple SL, Isaacs JT.

Prostate. 2014 Aug;74(11):1118-31. doi: 10.1002/pros.22828. Epub 2014 Jun 9.

32.

4-Hy-droxy-5-meth-oxy-N,1-dimethyl-2-oxo-N-[4-(tri-fluoro-meth-yl)phen-yl]-1,2-di-hydro-quinoline-3-carboxamide.

Akinboye ES, Butcher RJ, Yildirim SO, Isaacs JT.

Acta Crystallogr Sect E Struct Rep Online. 2014 Feb 15;70(Pt 3):o297-8. doi: 10.1107/S1600536814003031. eCollection 2014 Mar 1.

33.

Enhancement of the T-cell armamentarium as a cell-based therapy for prostate cancer.

Brennen WN, Drake CG, Isaacs JT.

Cancer Res. 2014 Jul 1;74(13):3390-5. doi: 10.1158/0008-5472.CAN-14-0249. Epub 2014 Apr 18.

34.

Androgen withdrawal fails to induce detectable tissue hypoxia in the rat prostate.

Regter S, Hedayati M, Zhang Y, Zhou H, Dalrymple S, Koch CJ, Isaacs JT, DeWeese TL.

Prostate. 2014 Jun;74(8):805-10. doi: 10.1002/pros.22803. Epub 2014 Mar 27.

35.

Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment.

Brennen WN, Denmeade SR, Isaacs JT.

Endocr Relat Cancer. 2013 Aug 23;20(5):R269-90. doi: 10.1530/ERC-13-0151. Print 2013 Oct. Review.

36.

Cancer. Prostate cancer takes nerve.

Isaacs JT.

Science. 2013 Jul 12;341(6142):134-5. doi: 10.1126/science.1241776. No abstract available.

PMID:
23846894
37.

Of mice and men--warning: intact versus castrated adult male mice as xenograft hosts are equivalent to hypogonadal versus abiraterone treated aging human males, respectively.

Michiel Sedelaar JP, Dalrymple SS, Isaacs JT.

Prostate. 2013 Sep;73(12):1316-25. doi: 10.1002/pros.22677. Epub 2013 Jun 15.

38.

Quantification of Mesenchymal Stem Cells (MSCs) at sites of human prostate cancer.

Brennen WN, Chen S, Denmeade SR, Isaacs JT.

Oncotarget. 2013 Jan;4(1):106-17.

39.

Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment.

Isaacs JT, Antony L, Dalrymple SL, Brennen WN, Gerber S, Hammers H, Wissing M, Kachhap S, Luo J, Xing L, Björk P, Olsson A, Björk A, Leanderson T.

Cancer Res. 2013 Feb 15;73(4):1386-99. doi: 10.1158/0008-5472.CAN-12-2730. Epub 2012 Nov 13.

40.

Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug.

Brennen WN, Rosen DM, Wang H, Isaacs JT, Denmeade SR.

J Natl Cancer Inst. 2012 Sep 5;104(17):1320-34. doi: 10.1093/jnci/djs336. Epub 2012 Aug 21.

41.

Engineering enzymatically activated "molecular grenades" for cancer.

Denmeade SR, Isaacs JT.

Oncotarget. 2012 Jul;3(7):666-7.

42.

Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy.

Denmeade SR, Mhaka AM, Rosen DM, Brennen WN, Dalrymple S, Dach I, Olesen C, Gurel B, Demarzo AM, Wilding G, Carducci MA, Dionne CA, Møller JV, Nissen P, Christensen SB, Isaacs JT.

Sci Transl Med. 2012 Jun 27;4(140):140ra86. doi: 10.1126/scitranslmed.3003886. Erratum in: Sci Transl Med. 2012 Jul 18;4(143):143er4.

43.

Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer.

Isaacs JT, D'Antonio JM, Chen S, Antony L, Dalrymple SP, Ndikuyeze GH, Luo J, Denmeade SR.

Prostate. 2012 Oct 1;72(14):1491-505. doi: 10.1002/pros.22504. Epub 2012 Mar 6.

44.

Human prostate cancer initiating cells isolated directly from localized cancer do not form prostaspheres in primary culture.

Chen S, Principessa L, Isaacs JT.

Prostate. 2012 Sep 15;72(13):1478-89. doi: 10.1002/pros.22503. Epub 2012 Mar 6.

45.

Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy.

Brennen WN, Isaacs JT, Denmeade SR.

Mol Cancer Ther. 2012 Feb;11(2):257-66. doi: 10.1158/1535-7163.MCT-11-0340. Review.

46.

Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts.

Dalrymple SL, Becker RE, Zhou H, DeWeese TL, Isaacs JT.

Prostate. 2012 May 1;72(6):638-48. doi: 10.1002/pros.21467. Epub 2011 Aug 11.

47.

The "infectious" nature of human prostate cancer: a cautionary note.

Sfanos KS, Isaacs JT.

Oncotarget. 2011 Apr;2(4):281-3. No abstract available.

48.

Enzymatically active prostate-specific antigen promotes growth of human prostate cancers.

Williams SA, Jelinek CA, Litvinov I, Cotter RJ, Isaacs JT, Denmeade SR.

Prostate. 2011 Nov;71(15):1595-607. doi: 10.1002/pros.21375. Epub 2011 Mar 10.

49.
50.

Loss of androgen receptor-dependent growth suppression by prostate cancer cells can occur independently from acquiring oncogenic addiction to androgen receptor signaling.

D'Antonio JM, Vander Griend DJ, Antony L, Ndikuyeze G, Dalrymple SL, Koochekpour S, Isaacs JT.

PLoS One. 2010 Jul 8;5(7):e11475. doi: 10.1371/journal.pone.0011475.

Supplemental Content

Loading ...
Support Center